Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

iodine-131-tositumomab

Known as: I 131 Monoclonal Antibody Anti-B1, tositumomab iodine i 131, Iodine I 131 Monoclonal Antibody Anti-B1 
A monoclonal antibody (tositumomab) that has been chemically changed by adding radioactive iodine, and that is used in the treatment of certain types… Expand
National Institutes of Health

Related topics

Related topics

7 relations

Broader (2)

Antineoplastic AgentsMonoclonal Antibodies

Narrower (1)

Bexxar
Human B-Lymphocyte Antigen CD20, humanNCIt Antineoplastic Agent TerminologyTositumomab and Iodine I 131 Tositumomab Therapytositumomab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for…
PURPOSE This clinical trial evaluated standard-dose radioimmunotherapy with a chemotherapy-based transplantation regimen followed… Expand
  • figure 1
  • table 1
  • figure 2
  • table 3
  • figure 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.
PURPOSE Advanced follicular lymphomas (FL) are considered incurable with conventional chemotherapy and there is no consensus on… Expand
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Marketed therapeutic antibodies compendium
Therapeutic monoclonal antibodies (mAbs) are currently being approved for marketing in Europe and the United States, as well as… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
131I-tositumomab therapy as initial treatment for follicular lymphoma.
BACKGROUND Advanced-stage follicular B-cell lymphoma is considered incurable. Anti-CD20 radioimmunotherapy is effective in… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas.
PURPOSE This study is an integrated efficacy analysis of the five clinical trials of tositumomab and iodine-131 tositumomab in… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab.
PURPOSE To determine overall response (OR) and complete response (CR) rates, response duration, progression-free (PFS) and… Expand
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma.
OBJECTIVE The objective of this study was to evaluate the technique, efficacy, and side effects of percutaneous ethanol injection… Expand
Is this relevant?
Highly Cited
2001
Highly Cited
2001
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59.
Complement-dependent cytotoxicity is thought to be an important mechanism of action of the anti-CD20 monoclonal antibody… Expand
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
Abstract Anti-CD20 monoclonal antibodies have been successfully employed in the clinical treatment of non-Hodgkin's lymphomas in… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 4
  • figure 3
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.
PURPOSE This multicenter phase II study evaluated the efficacy, dosimetry methodology, and safety of iodine-131 tositumomab in… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE